GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy

Study Identifier
MAF/AGN/OPH/GLA/027
CT.gov Identifier
NCT01628601
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • Fixed combination 0.3 mg bimatoprost and 5 mg timolol
    • Phase
    N/A
    Sex
    Female & Male
    Age
    N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of primary open angle glaucoma or ocular hypertension * Prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol)
    Exclusion Criteria:
    * None

    Protocol Summary

    This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3 mg bimatoprost and 5 mg timolol) by their physician.

    Study Locations

    Location
    Status
    Location
    Vienna, Austria
    Status
    Not applicable